Erratum: Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: Application of a matching-adjusted indirect comparison (Applied Health Economics and Health Policy (2012) 10:6 (381-395) DOI: 10.2165/11641870-000000000-00000);Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficithyperactivity disorder: Application of a matching-adjusted indirect comparison

Applied Health Economics and Health Policy

Volumn 10, Issue 6, 2012, Pages 381-395

  Haim Erder, M ^a   Xie, Jipan ^b   Signorovitch, James E ^b   Chen, Kristina S ^b   Hodgkins, Paul ^a   Lu, Mei ^b   Wu, Eric Q ^b   Sikirica, Vanja ^a  

^a SHIRE   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Children; Cost effectiveness; Guanfacine

Indexed keywords

EID: 84868274294     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0015-3     Document Type: Erratum

References (41)

1. Centers for Disease Control and Prevention. Attentiondeficit/ hyperactivity disorder (ADHD) data and statistics [online]. Available from URL: http://www.cdc.gov/ncbddd/adhd/data.html [Accessed 2012 Jan 06]
2. Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention deficit hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry 2012 Oct; 51 (10): 990-1002
3. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepi-demiol Drug Saf 2001 Mar-Apr; 10 (2): 85-94 (Pubitemid 32590939)
4. Findling RL. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin Ther 2008 May; 30 (5): 942-57 (Pubitemid 351799870)
5. Strattera® (atomoxetine hydrochloride) capsules for oral use [package insert]. Available from URL: http://pi.lilly.com/us/strattera-pi.pdf [Accessed on 2012 Oct 09]
6. INTUNIV® (guanfacine) extended-release tablets [package insert]. Available from URL: http://pi.shirecontent.com/PI/PDFs/Intuniv-USA-ENG.pdf [Accessed on 2012 Oct 09]
7. Michelson D, Faries D, Wernicke J, et al., Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108 (5): E83
8. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896-901 (Pubitemid 35283256)
9. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, control-controlled study of guanfacine ex tended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008 Jan; 121 (1): E73-84
10. Sallee F, McGough J, Wigal T, et al., on behalf of the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a control-controlled trial. J Am Acad Child Ado-lesc Psychiatry 2009 Feb; 48 (2): 155-65
11. Wu EQ, Hodgkins P, Ben-Hamadi R, et al. Cost effectiveness of pharmacotherapies for attention-deficit hyper-activity disorder: a systematic literature review. CNS Drugs 2012; 26 (7): 1-20
12. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeco-nomics 2010; 28 (10): 935-45
13. Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin 2011; 27 (6): 1263-71
14. Signorovitch JE, Wu EQ, Swallow E, et al. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig 2011; 31 (9): 665-74
15. Signorovitch J, Erder MH, Xie J, et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Phar-macoepidemiol Drug Saf 2012; 21 (S2): 130-7
16. Signorovitch J, Sikirica V, Erder MH, et al. Matchingadjusted indirect comparisons: a new tool for timely comparative effectiveness. Value Health 2012 Sep; 15 (6): 940-7
17. Efron B, Tibshirani R. An introduction to the bootstrap. Boca Raton, FL: Chapman & Hall/CRC Press, 1993
18. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114 (1): e1-8
19. Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 2004; 8 (45): 45-52 (Pubitemid 40081859)
20. Spencer T, Biederman J, Heiligenstein J, et al. An openlabel, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11 (3): 251-65 (Pubitemid 32937637)
21. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomox-etine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63: 1140-7 (Pubitemid 36084059)
22. Prasad S, Arellano J, Steer C, et al. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK. Int J Clin Pract 2009; 63 (7): 1031-40
23. Newcorn JH, Sutton V, Weiss MD, et al. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the integrated data exploratory analysis (IDEA) Study. J Am Acad Child Adolesc Psychiatry 2009; 48 (5): 511-8
24. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006 Jul; 10 (23): iii-iv,xiii-146
25. Coghill D, Spender Q, Barton J, et al. Measuring quality of life in children with attention-deficit-hyperactivity disorder in the United Kingdom. Poster presented at the 16th World Congress of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP); 2004 Aug 23-26; Berlin
26. Siddique R, Markowitz J, Engelhart L. Impact of atypical antipsychotic drug sedation on quality of life. Atlanta, GA: American Psychiatric Association, 2005
27. Evans KW. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharma-coeconomics 1997; 12 (5): 565-77 (Pubitemid 27471145)
28. Butler JM, Rapp SR, Shaw EG. Managing the cognitive effects of brain tumor radiation therapy. Curr Treat Options Oncol 2006; 7 (6): 517-23 (Pubitemid 44697788)
29. Lloyd A, Nafees B, Narwska J, et al. Health state utilities for metastic breast cancer. Br J Cancer 2006; 95: 683-90 (Pubitemid 44373482)
30. Anderson JP, Moser RJ. Parasite screening and treatment among Indochinese refugees: cost-benefit/utility and the General Health Policy Model. JAMA 1985; 253 (15): 2229-35 (Pubitemid 15119140)
31. Selai C, Trimble M, Kaiser S, et al. New anti-epilipetic drugs: clinical outcomes and utility scores [poster P330]. 5th European Congress on Epileptology; 2002 Oct 6-10; Madrid
32. Spencer TJ, Newcorn JH, Kratochvil C, et al. Effects of atomoxetine on growth after 2-year treatment among pe-diatric patients with attention-deficit/hyperactivity disorder. Pediatrics 2005; 116: e74-80
33. Medi-Span®. Master Drug Data Base v2.5 (MDDB®). Indianapolis (IN): Medi-Span® [online]. Available from URL: http://www.medispan.com/ master-drug-database.aspx [Accessed 2011 Jul 22]
34. Guevara J, Lozano P, Wikizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108 (1): 71-8 (Pubitemid 32592007)
35. Biederman J, Melmed RD, Patel A, et al. Long-term, openlabel extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008 Dec; 13 (12): 1047-55
36. Sallee F, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009 Jun; 19 (3): 215-26
37. Market share of different dosing forms of atomoxetine. Wayne, PA: Shire Development, LLC, 2011. (Data on file)
38. United States Department of Labor, Bureau of Labor Statistics. Consumer price index databases [online]. Available from URL: http://www.bls.gov/cpi/data. htm [Accessed 2012 Jun 06]
39. Hlatky MA, Owens DK, Sanders GD. Cost-effectiveness as an outcome in randomized clinical trials. Clinical Trials 2006; 3 (6): 543-51
40. Daily average consumption of guanfacine extended release and atomoxetine. Wayne, PA: Shire Development, LLC, 2011. (Data on file)
41. Teutsch SM, Berger ML, Weinstein MC. Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood) 2005; 24 (1): 128-32 (Pubitemid 40169780)